Cliff Asness's DNLI Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 102,579 shares of Denali Therapeutics Inc. (DNLI) worth $1.97 M, representing 0.00% of the portfolio. First purchased in 2019-Q2, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in DNLI, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 64,141 shares. Largest reduction occurred in Q4 2021, reducing 30,382 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Denali Therapeutics (DNLI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Denali Therapeutics (DNLI) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +64,141 | Add 166.87% | 102,579 | $19.20 |
| Q4 2025 | +14,299 | Add 59.24% | 38,438 | $16.51 |
| Q3 2025 | +2,922 | Add 13.77% | 24,139 | $14.52 |
| Q2 2025 | +21,217 | New Buy | 21,217 | $13.99 |
| Q4 2024 | -16,018 | Sold Out | 0 | $0.00 |
| Q3 2024 | +16,018 | New Buy | 16,018 | $29.13 |
| Q2 2024 | -11,001 | Sold Out | 0 | $0.00 |
| Q1 2024 | +11,001 | New Buy | 11,001 | $20.52 |
| Q3 2023 | -8,165 | Sold Out | 0 | $0.00 |
| Q2 2023 | -1,036 | Reduce 11.26% | 8,165 | $29.51 |
| Q1 2023 | +9,201 | New Buy | 9,201 | $23.04 |
| Q2 2022 | -22,686 | Sold Out | 0 | $0.00 |
| Q1 2022 | -28,981 | Reduce 56.09% | 22,686 | $32.18 |
| Q4 2021 | -30,382 | Reduce 37.03% | 51,667 | $44.59 |
| Q3 2021 | +2,765 | Add 3.49% | 82,049 | $50.45 |
| Q2 2021 | -7,340 | Reduce 8.47% | 79,284 | $78.44 |
| Q1 2021 | +22,757 | Add 35.63% | 86,624 | $57.10 |
| Q4 2020 | +12,620 | Add 24.63% | 63,867 | $83.75 |
| Q3 2020 | +22,370 | Add 77.47% | 51,247 | $35.83 |
| Q2 2020 | +2,047 | Add 7.63% | 28,877 | $24.17 |
| Q1 2020 | -22,375 | Reduce 45.47% | 26,830 | $17.52 |
| Q4 2019 | -19,789 | Reduce 28.68% | 49,205 | $17.42 |
| Q3 2019 | +58,648 | Add 566.87% | 68,994 | $15.32 |
| Q2 2019 | +10,346 | New Buy | 10,346 | $20.78 |
Cliff Asness's Denali Therapeutics Investment FAQs
Cliff Asness first purchased Denali Therapeutics Inc. (DNLI) in Q2 2019, acquiring 10,346 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Denali Therapeutics Inc. (DNLI) for 24 quarters since Q2 2019.
Cliff Asness's largest addition to Denali Therapeutics Inc. (DNLI) was in Q1 2026, adding 102,579 shares worth $1.97 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 102,579 shares of Denali Therapeutics Inc. (DNLI), valued at approximately $1.97 M.
As of the Q1 2026 filing, Denali Therapeutics Inc. (DNLI) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Denali Therapeutics Inc. (DNLI) was 102,579 shares, as reported at the end of Q1 2026.